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Introduction
It is estimated that over 325,000 spinal fusions (137,000
cervical and 162,000 lumbar) are performed yearly in the
US [1]. Clinical interest in the use of total disc replacement
(TDR) instead of spinal fusion for the treatment of painful
lumbar degenerative disc disease has grown in recent years.
In the United States, two lumbar disc prostheses (Charite,
Johnson & Johnson, LeLocle; Prodisc-L, Synthes,
Solothurn, Switzerland) are currently approved for clinical
use by the Food and Drug Administration (FDA). There are
also two cervical TDR prostheses currently FDA approved
for clinical use (Prestige-ST, Medtronic Sofamor Danek,
Memphis, TN; Prodisc-C, Synthes). Multiple other lumbar
and cervical TDR prostheses are in various stages of clini-
cal trials [2-7]. Several recent reports have documented the
clinical efficacy of both lumbar and cervical TDR
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S St tu ud dy y D De es si ig gn n:: Retrospective chart review.
P Pu ur rp po os se e:: To evaluate the incidence of potential total disc replacement (TDR) candidates among cervical and lumbar fusion
patient populations using strict Food and Drug Administration (FDA) criteria and with relative exclusion criteria removed. 
O Ov ve er rv vi ie ew w o of f L Li it te er ra at tu ur re e:: Recent studies suggest that the potential percentage of patients that are candidates for TDR ranges
from 0-5% in lumbar fusions and 43% in cervical fusions.
M Me et th ho od ds s:: We performed a retrospective chart review of 280 consecutive patients who had lumbar (n = 174) and cervical (n
= 106) fusion or TDR performed by one of four independent adult orthopaedic spine surgeons. Charts were screened for
investigational device exemption (IDE) inclusion/exclusion criteria and later reanalyzed excluding relative exclusion criteria,
such as history of chronic medical illness, twolevel disease (cervical cases), and history of prior fusion surgery in the
anatomic region. 
R Re es su ul lt ts s:: Of the 174 lumbar surgeries, 10 were TDR with Prodisc-L and 164 were lumbar fusions. The most common TDR
exclusion criteria were lytic spondylolisthesis or spinal stenosis (47.7% of patients) and more than 2 level degenerative disc
disease (37.9%). 14.9% had no IDE exclusion criteria and would be considered candidates for TDR. After excluding the rela-
tive lumbar exclusion criteria, this percentage increased to 25.8%. Of the 106 cervical cases, 3 had a TDR with Prodisc-C
and 103 had a cervical fusion. Twenty eight percent had no IDE exclusion criteria and would be considered candidates for
cervical TDR. 
C Co on nc cl lu us si io on ns s:: A larger percentage of cervical fusion candidates are potential candidates for TDR (28%) than lumbar fusion
candidates (14.9%) based on the strict IDE criteria. 
Key W Words: Total disc replacement, Incidence, Inclusion/exclusion criteria, Contraindications, Cervical and lumbar fusions[2,3,6,8,9]. 
The theoretical benefit of TDR is to maintain motion in
clinical situations where spinal stabilization is indicated.
Potentially, this continued motion allows the spine as a
whole to function more normally than with fused segments,
and it may also limit the additional stresses seen in the
motion segments adjacent to fusions, diminishing problems
associated with later adjacent segment degeneration. It is
generally felt that the increase in TDR procedures over time
will result from three forces. One is a growing pool of sur-
geons trained to perform TDR procedures. The other two
forces are an expanded pool of patients willing to undergo
the procedure (as opposed to fusion), and an expansion of
the possible clinical indications for use beyond the strict
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Table 1. Prodisc-L IDE Study Exclusion Criteria 
1. DDD of more than one or two diseased levels being treated
2. Known allergy to titanium, polyethylene, cobalt, chromium or molybdenum
3. History of  prior fusion surgery at any lumbar level
4. Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
5. Radiographic confirmation of facet joint disease or degeneration
6. Lytic spondylolisthesis or spinal stenosis
7. Degenerative spondylolisthesis of grade > 1
8. Back or leg pain of unknown etiology
9. History of osteoporosis (A DEXA bone density measured T score < -1.0) or history of osteoporosis medications or Osteo-
porotic fractures in the past
10. History of metabolic bone disease (including Paget’s disease and Osteomalacia)
11. History of morbid obesity (defined as a body mass index > 40 or a weight more than 100 lbs. over ideal body weight)
12. History of any active infection (systemic or local)
13. Known rheumatoid arthritis or other autoimmune disease
14. History of chronic systemic disease including AIDS, HIV, hepatitis
15. History of any active malignancy except non-melanoma skin cancer (minimum of 5 year disease-free interval for any past
malignancies treated with curative intent) 
IDE: Investigational device exemption, AIDS: Acquired immune deficiency syndrome, HIV: Human immunodeficiency virus.
Table 2. Prodisc-C IDE Study Exclusion Criteria
1. More than one vertebral level being treated 
2. Cervical instability on resting lateral or flexion/extension radiographs (translation greater than 3 mm and/or greater than 11
degrees of rotational difference to that of either adjacent level)
3. Presence of a fused level adjacent to the level to be treated 
4. Radiographic confirmation of severe facet joint disease or degeneration
5. Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene
6. Known prior fracture of one or both vertebral levels to be treated
7. Prior surgery at the level to be treated
8. Severe spondylosis at the level to be treated as characterized by any of the following:
- Bridging osteophytes
- Disc height loss greater than 50%
- Absence of motion on flexion-extension radiographs (< 2� )
9. Neck or arm pain of unknown etiology
10. History of Osteoporosis (A DEXA bone density measured T score < -1.0) or history of osteoporosis medications or Osteo-
porotic fractures in the past
11. History of metabolic bone disease (including Paget’s disease and osteomalacia)
12. Severe diabetes mellitus reuiring daily insulin management
13. History of any active infection (systemic or local)
14. Known rheumatoid arthritis or other autoimmune disease
15. History of chronic systemic disease including AIDS, HIV, Hepatitis
16. History of any active malignancy except non-melanoma skin cancer (minimum of 5 year disease-free interval for any past
malignancies treated with curative intent)
IDE: Investigational device exemption, AIDS: Acquired immune deficiency syndrome, HIV: Human immunodeficiency virus.FDA study criteria for the initial clinical trials [10-13].
When designing investigational device exemption (IDE)
studies for intervertebral disc arthroplasty, a myriad of
inclusion and exclusion criteria are enforced in order to
strictly define the study patient population and remove
potential confounding clinical variables (Tables 1 and 2).
Recent series have shown that only 5% or less of some sur-
geon’s series of lumbar surgical patients had no contraindi-
cations to TDR [10]. No previous studies have fully quanti-
fied the prevalence of each exclusion criteria for lumbar and
cervical TDR.
The purpose of this study was to evaluate a large popula-
tion of adult spinal fusion patients combined from four
independent general adult spine surgical practices to deter-
mine the relative incidence of potential TDR candidates
among both cervical and lumbar fusion patients using both
the strict IDE study criteria as well as potential additional
relative indications for use. 
Materials and Methods 
We performed a retrospective chart review of 280 consec-
utive patients who had lumbar (n = 174) and cervical (n =
106) fusion or TDR procedures performed by four indepen-
dent adult orthopaedic spine surgeons working within a sin-
gle academic institution. Three of the four surgeons perform
TDR in their practice as investigators in the prospective,
randomized cervical and lumbar Prodisc IDE studies. As all
TDR patients were assumed to have been candidates for
fusion procedures as well, the patients who underwent TDR
procedures during this set time interval were also included
in the analysis in order to consecutively capture all cervical
and lumbar spine fusion candidates who underwent surgery
during the period of study. This was necessary in order to
arrive at valid incidence data for potential TDR patients
among spinal fusion candidates.
Full chart review included examination of demographic
data, complete medical history, physical exam, reports of all
diagnostic studies, and review of all operative data. This
allowed for the complete evaluation of all inclusion and
exclusion criteria for the Prodisc cervical and lumbar TDR
IDE study protocols for all patients, as well as a complete
listing of all of the specific exclusion criteria for which a
patient would not be a TDR candidate.
In the secondary analysis, certain exclusion criteria were
considered relative rather than absolute and were removed,
revealing additional patients which might be TDR candi-
dates (Table 3). Criteria were considered relative if they
were not exclusion criteria for IDE trials for other TDR
devices. For potential lumbar TDR candidates, this included
prior history of lumbar fusion at an adjacent or distant level.
For cervical TDR candidates, this included prior history of
cervical fusion at an adjacent or distant level, two-level dis-
ease (candidate for 2-level TDR), and prior posterior cervi-
cal decompression at the index level(s) to be treated. Other
criteria considered relative include chronic diseases not
affecting the bone quality of the vertebral column and
active nonspinal infection (which can be treated prior to
TDR), which are common FDA study exclusion criteria in
order to limit confounding outcome variables, but are
unlikely to specifically affect TDR performance in patients.
Significant facet arthrosis, osteoporosis, spinal stenosis,
spinal instability (including spondylolysis), spinal deformi-
ty, and greater than 2 level disease were still considered
absolute contraindications for TDR. 
Data analysis was performed using Microsoft Excel 2003
(Microsoft Inc., Redmond, WA, USA). Statistical testing
was performed by a two tailed student’s t-test assuming
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Table 3. Exclusion criteria considered relative for cervical and lumbar TDR
Lumbar TDR Cervical TDR
Prior lumbar fusion Two level spondylosis/HNP requiring treatment
History of metabolic bone disease Prior cervical fusion
History of insulin dependent diabetes Prior posterior surgery at the treated level
History of any active non-spinal infection History of metabolic bone disease
History of RA or other autoimmune disease History of Insulin dependent diabetes
History of chronic disease History of any active non-spinal infection
History of active malignancy History of RA or other autoimmune disease
History of chronic disease
History of active malignancy
TDR: Total disc replacement, RA: Rheumatoid arthritis. unequal variances. Statistical significance was defined as p
< 0.05. 
Results
Of a total of 280 patient charts reviewed, 174 were lum-
bar cases and 106 were cervical. Of the 174 lumbar surg-
eries, 164 (94.5%) were lumbar fusions and 10 (5.3%)
patients underwent TDR.  Of the 106 cervical patients, 103
(97.2%) underwent cervical fusions and 3 (2.8%) had a
TDR. For all patients, 48% were male and 52% were
female. Mean age for all patients was 51 years. Similar
breakdowns were seen for these demographics in the lum-
bar and cervical subgroups. 
Two hundred and twenty eight of the 280 cases had one
or more exclusion criteria. For all 280 cases, the average
number of TDR exclusion criteria per patient was of 1.6
(range, 0 to 16). For patients with one or more exclusion
criteria, the average number of TDR exclusion criteria per
patient was 2 (range, 1 to 16). The average number of TDR
exclusion criteria per patient with more than one (≥ 2) and
two (≥ 3) exclusion criteria, was 2.7 and 3.6 respectively.
The number of patients excluded for each specific exclusion
criteria and the incidence of TDR candidates can be seen in
Tables 4 and 5. 
In the potential lumbar TDR patient population, the most
common TDR exclusion criteria were lytic spondylolisthe-
sis or spinal stenosis (47.7% of patients) followed by more
than 2 level degenerative disc disease requiring treatment
(37.9%), and prior lumbar fusion (28.7%). Of all 174 lum-
bar cases, 14.9% (26 patients) had no IDE exclusion criteria
and would be considered candidates for TDR. 85.1% had
one or more contraindication. After removing the relative
lumbar exclusion criteria, the percentage of potential TDR
candidates increased to 25.9% (45 cases).
Among the potential cervical TDR patients, the most
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Table 4. Percentage of patients with the various IDE Exclusion Criteria in lumbar fusion and TDR patients
Lumbar Exclusion Criteria  Fusion (n = 164) TDR (n = 10) Total (n = 174)
DDD greater than 2 levels being treated 40.2 20 37.9
Known allergy to prosthetic materials 01.8 00 01.7
History of prior lumbar fusion-any level 30.5 00 28.7
Vertebral body compromise 05.5 00 05.2
Facet joint degeneration 14.6 10 13.7
Lytic spondylolisthesis or spinal stenosis 50.6 00 47.7
Degenerative spondylolisthesis  08.53 00 08.04
Back or leg pain of unknown etiology 00 00 00
History of osteoporosis 03.7 00 03.4
History of metabolic bone disease 02.5 00 02.3
Morbid obesity 03.65 00 03.4
History of any active infection 04.3 00 04
History of RA or other autoimmune disease 03.7 00 03.4
History of chronic disease 04.3 00 04
History of active malignancy 04 00 04
With one or more exclusion criteria 88.5 30 85.1
Without any exclusion criteria 11.5 70 14.9
Without absolute exclusion criteria (excluding relative contraindications) 23.2 70 25.8
Vaues are presented as percentage.
IDE: Investigational device exemption, TDR: Total disc replacement, RA: Rheumatoid arthritis.
Table 5. Percentage of patients with one or more contraindications
No. of  Lumbar with all  Lumbar without  Cervical with all  Cervical without relative 
contraindications contraindication relative contraindications contraindication contraindications
≥ 18 5 7 4 7 2 6 1
≥ 25 2 1 9 3 2 04
≥ 32 2 051 6 02
Vaues are presented as percentage.common TDR exclusion criteria were greater than one level
disease (45.2%), severe spondylosis at the treated level
(22.7%), and prior cervical fusion (20.8%). Of all 106 cer-
vical cases, 28% (30 cases) had no IDE exclusion criteria
and would be considered candidates for cervical TDR. After
excluding the relative cervical exclusion criteria, the per-
centage of potential candidates increased to 39% (41 cases)
(Table 6).
Discussion
This study found a higher percentage of cervical fusion
patients to be candidates for cervical TDR than lumbar
fusion patients, both utilizing the strict FDA trial indica-
tions and with additional relative indications added. This is
not surprising given the current use of and indications for
lumbar and cervical fusions. Lumbar fusions done for pre-
dominantly back pain due to painful degenerative disc dis-
ease, which might be potential TDR cases, represent a small
percentage of all lumbar fusions in most general adult spine
surgery practices. The majority of lumbar fusions are per-
formed for more advanced degeneration with concomitant
facet disease and spinal instability as seen with degenerative
spondylolisthesis or scoliosis, and would be absolutely con-
traindicated for TDR. Cervical fusions done following dis-
cectomy to relieve primarily arm pain with or without con-
comitant neck pain, which might be candidates for cervical
TDR, represent a higher percentage of overall cervical
fusions. Cervical fusions for isolated neck pain without
advanced spondylosis or instability are quite uncommon,
and were not an approved indication for TDR in the
Prodisc-C IDE trial.
Specific clinical and radiographic factors were considered
absolute contraindications for use of cervical and lumbar
TDR currently. Osteoporosis (T score < -1.0) and other
metabolic bone diseases will have a higher rate of implant
subsidence and vertebral fracture. Prior disc space infection
may harbor latent organisms and be at higher risk of infec-
tion following TDR. Pain associated with advanced spondy-
losis with facet joint arthrosis is unlikely to improve follow-
ing TDR, leaving the facets mobile. Segmental instability,
with or without deformity (spondylolisthesis or scoliosis),
will place added stress on the implant and may result in
early and increased likelihood of failure. Clinically signifi-
cant lumbar spinal stenosis is commonly associated with
advanced facet arthrosis and requires direct decompression.
If stabilization is needed, there are usually concomitant
advanced degenerative facet changes or segmental instabili-
ty present.
The exclusion criteria considered relative and examined
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Table 6. Percentage of patients with the various IDE exclusion criteria in cervical fusion and TDR patients
Cervical Exclusion Criteria  Fusion (n = 103) TDR (n = 3) Total (n = 106)
DDD greater than 1 level being treated 46.6 0 45.2 
Radiographic cervical instability 08.7 0 08.4
Prior adjacent cervical fusion  20.4 0 19.8
Facet joint degeneration 10.7 0 10.3
Known allergy to prosthetic materials  000 00
Vertebral body compromise 09.7 0 09.4
Prior surgery at the treated level 10.7 0 10.3
Severe spondylosis at treated level 21.4 0 20.8
Neck or arm pain of unknown etiology 000 00
History of osteoporosis 01.9 0 01.9
History of metabolic bone disease 000 00
History of insulin dependent diabetes  000 00
History of any active infection 01.9 0 01.9
History of RA or other autoimmune disease 05.8 0 05.7
History of chronic disease 01.9 0 01.9
History of active malignancy 00.7 0 00.9
With one or more exclusion criteria 74 0 72
Without any exclusion criteria 26 100 28
Without absolute exclusion criteria (excluding relative contraindications) 37 100 39
Vaues are presented as percentage.
IDE, investigational device exemption; TDR, total disc replacement; RA, rheumatoid arthritis.as potential new indications were chosen based on both the
differing inclusion criteria of other current TDR IDE trials
as well as the real world practice of medicine outside of
clinical trials.  Patients with a history of chronic illness such
as insulin dependent diabetes, rheumatoid arthritis, and
other autoimmune disease, are excluded from FDA trials
but may otherwise be excellent candidates for TDR follow-
ing a thorough assessment of bone quality. Patients with
active non-spinal infection or malignancy may be TDR can-
didates, all other things considered, once their active non-
spine disease is treated and adequately controlled.  Two-
level lumbar disease was included in the IDE study and kept
as part of the lumbar inclusion criteria for this analysis
despite the fact that, as of the time of the writing of this
manuscript, the two-level data has not been fully reviewed
by the FDA and so this is not yet an approved indication.
Two-level disease, common in the cervical spine, was not
included in the FDA IDE trial, so it was considered a rela-
tive indication. TDR next to a prior adjacent or nonadjacent
fusion was an exclusion criteria for both of the Prodisc IDE
trials. However, it is an acceptable inclusion criteria for
other cervical and lumbar TDR IDE trials, and so it was
considered a relative indication for this analysis. Prior pos-
terior decompressive surgery at the index level was consid-
ered an exclusion criterion for the Prodisc-C IDE trial but
not for the Prodisc-L trial, so it was made a relative indica-
tion for the cervical patients in the secondary analysis.
Other studies looking at the potential incidence of TDR
candidates have provided varying results. Huang et al. [10],
reviewing 100 consecutive lumbar surgical procedures,
found only 5% of patients without contraindications for
TDR.2 This series, however, also included 44 patients who
underwent nonfusion surgical procedures including decom-
pressions (in 42 of the patients), IDET (4 patients), and
lumbar TDR (1). All of their fusion patients (100%) also
underwent spinal canal decompressions, so no fusion cases
were done for back pain only. Although none of their
fusions cases had no contraindications for TDR, if the TDR
case and 4 IDET cases are included (which should have no
TDR contraindications), then the true number of fusion-
indicated cases rises to 61 and the number of potential TDR
candidates in that group rises to 5, or 8% of ‘possible’
fusion cases. 
Wong et al. [14], reviewing 100 consecutive 1-3 level
lumbar fusions, found at least one contraindication in every
patient (with an average number of 3.64 contraindications
per patient), leaving none as potential TDR candidates.
Facet disease was noted as a contraindication in 97 patients,
but was only felt to be definitely clinically significant in 9.
Seventy-five of the cases had fusion surgery for spondy-
lolisthesis, 31 cases had a herniated disc with radiculopathy,
15 cases had scoliosis, 16 had deficient posterior elements,
and 2 were done for pseudoarthrosis. It is likely, given the
contraindications reported, that few if any of the reviewed
fusions performed by these 5 spine surgeons (3 orthopedic,
2 neurological) were performed for the diagnosis of disco-
genic low back pain. 
Chin [15] presented a similar study in which he analyzed
the presence of the FDA exclusion/inclusion criteria on
potential surgical candidates for lumbar spine surgery. He
concludes that there was only a 0.5% incidence of indica-
tions for TDR in the overall population screened (627
patients). It is important to point out that only 21% of these
patients were candidates for surgery, and that only 9% had a
spinal fusion. When analyzing the data on his fusion
patients, he reports a 5% incidence of no contraindications.
This study does not describe how the clinical significance
of each contraindication may interfere with the incidence
reported.
Auerbach et al. [16] reported a 43% incidence of no con-
traindications to cervical TDR using the current IDE inclu-
sion and exclusion criteria from 4 different cervical TDR
IDE trials. They also found that an additional 4.2% of
patients would have qualified as TDR candidates if treat-
ment for adjacent segment disease was included.
There are a variety of factors with have limited the wide-
spread acceptance of lumbar TDR to date. Insurance autho-
rization for the procedure has been very limited, often only
on a case by case basis. Even those cases where insurance
company authorization is possible are often approved only
for TDR within the strict FDA guidelines established by the
randomized control trial. Some have called for more long-
term data, which is not yet available in the United States
patient population. Finally, surgeons remain concerned over
the implant longevity and the difficulty with anterior revi-
sion procedures, if needed, especially for the lumbar spine. 
Conclusions
In our consecutive series of lumbar and cervical fusion
surgical candidate patients, a larger percentage of cervical
fusion candidates were found to be potential candidates for
TDR (28%) than lumbar fusion candidates (14.9%) based
on the strict IDE study inclusion and exclusion criteria.
218 / ASJ: Vol. 5, No. 4, 2011When potential relative contraindications are removed, the
percentage of potential TDR candidates rose in both groups,
with the percentage of cervical patients remaining higher
than lumbar patients (39% vs. 25.8%).
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